EHA 2024 | Should patients with certain ALL subtypes be considered for alloSCT irrespective of MRD status?
Nicolas Boissel, MD, PhD, Saint-Louis Hospital, Paris, France, discusses whether patients with acute lymphoblastic leukemia (ALL) who reach measurable residual disease (MRD)-negativity should receive allogeneic stem cell transplantation (alloSCT). Two studies investigating this concluded that MRD response after induction or consolidation therapy is a key predictor for the benefit of alloSCT, and monitoring MRD status at these time points led to a significant reduction in the rate of alloSCT in first remission for younger patients without compromising disease-free survival (DFS). Whether patients with some subtypes of ALL should receive alloSCT regardless of MRD status is unclear and will require further investigation. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
